TP53 and colorectal cancer: In addition, considering that hybrids 3e, 3i, and 3k caused G0/G1 phase arrest could imply that these molecules act as cytotoxic and cytostatic compounds, making them potential therapeutic alternatives or adjuvants in the treatment of colorectal cancer, even in those cases with resistance to conventional chemotherapy because of the lack of p53 expression or function.